Nationwide Follow-Up Survey of Neuro-Oncological Molecular Tumor Boards in Germany
Overview
A 2025 follow-up survey of German neuro-oncology centers reveals near-universal access to Molecular Tumor Boards (MTBs) with increased certification of neuro-oncology centers and broader adoption of standardized referral systems. Despite progress, challenges such as reimbursement barriers and heterogeneous MTB structures persist.
Background
Precision oncology tailors cancer treatment based on molecular tumor profiles, but neuro-oncology has lagged due to tumor heterogeneity and limited targeted therapies. Molecular Tumor Boards (MTBs) help interpret genomic data to guide personalized treatments and are now integral to oncology care. Since a 2022 survey highlighted variability and barriers in MTB implementation in Germany, advances including new targeted therapies and updated guidelines have influenced practice. This 2025 survey assesses current MTB integration and ongoing challenges in German neuro-oncology centers.
University Hospitals 74%, Teaching Hospitals 20%, Outpatient Centers 6%
DKG-Certified Neuro-Oncology Centers
91% (up from 71% in 2022)
MTB Access
In-house 74%, Referral 20%, No Access 6%
Standardized Referral Systems
46% of respondents
Key Findings
MTB access is nearly universal among respondents, with 74% hosting in-house MTBs and 20% referring patients externally.
There is a significant increase in DKG-certified neuro-oncology centers from 71% in 2022 to 91% in 2025.
Standardized referral systems for MTB patient assignment are implemented in 46% of centers, indicating progress in workflow organization.
Respondents are predominantly experienced attending physicians, mainly neurosurgeons and neurologists, reflecting multidisciplinary involvement.
Despite advances, challenges such as reimbursement for off-label therapies and heterogeneous MTB structures remain barriers to optimal precision oncology integration.
Clinical Implications
The widespread availability of MTBs and increased certification of neuro-oncology centers support enhanced precision medicine delivery in Germany. Adoption of standardized referral pathways can improve patient selection and MTB efficiency. However, clinicians should remain aware of persistent barriers like reimbursement issues and variable MTB practices, which may impact implementation of molecularly guided therapies.
Conclusion
This follow-up survey demonstrates substantial progress in MTB integration within German neuro-oncology, marked by increased center certification and structured referrals. Continued efforts to address remaining challenges are essential to fully realize the benefits of precision oncology for brain tumor patients.
References
Weller et al. 2022 -- Nationwide Survey of Neuro-Oncological MTBs in Germany
INDIGO Trial 2023 -- Vorasidenib in IDH-Mutant Gliomas
EANO Guidelines 2023 -- Molecular Testing in Gliomas
ESMO 2024 -- Quality Indicators for Molecular Tumor Boards
